A DNA Repair and Cell Cycle Gene Expression Signature in Pediatric High-Grade Gliomas: Prognostic and Therapeutic Value.
DNA damage repair
PARP1
XRCC1
pediatric high-grade gliomas
prognostic clustering
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
07 May 2021
07 May 2021
Historique:
received:
01
03
2021
revised:
27
04
2021
accepted:
30
04
2021
entrez:
2
6
2021
pubmed:
3
6
2021
medline:
3
6
2021
Statut:
epublish
Résumé
Pediatric high-grade gliomas (pHGGs) are the leading cause of mortality in pediatric neuro-oncology, displaying frequent resistance to standard therapies. Profiling DNA repair and cell cycle gene expression has recently been proposed as a strategy to classify adult glioblastomas. To improve our understanding of the DNA damage response pathways that operate in pHGGs and the vulnerabilities that these pathways might expose, we sought to identify and characterize a specific DNA repair and cell-cycle gene expression signature of pHGGs. Transcriptomic analyses were performed to identify a DNA repair and cell-cycle gene expression signature able to discriminate pHGGs (n = 6) from low-grade gliomas (n = 10). This signature was compared to related signatures already established. We used the pHGG signature to explore already transcriptomic datasets of DIPGs and sus-tentorial pHGGs. Finally, we examined the expression of key proteins of the pHGG signature in 21 pHGG diagnostic samples and nine paired relapses. Functional inhibition of one DNA repair factor was carried out in four patients who derived H3.3 We identified a 28-gene expression signature of DNA repair and cell cycle that clustered pHGGs cohorts, in particular sus-tentorial locations, in two groups. Differential protein expression levels of PARP1 and XRCC1 were associated to We provide evidence that PARP1 overexpression, associated to XRCC1 expression,
Sections du résumé
BACKGROUND
BACKGROUND
Pediatric high-grade gliomas (pHGGs) are the leading cause of mortality in pediatric neuro-oncology, displaying frequent resistance to standard therapies. Profiling DNA repair and cell cycle gene expression has recently been proposed as a strategy to classify adult glioblastomas. To improve our understanding of the DNA damage response pathways that operate in pHGGs and the vulnerabilities that these pathways might expose, we sought to identify and characterize a specific DNA repair and cell-cycle gene expression signature of pHGGs.
METHODS
METHODS
Transcriptomic analyses were performed to identify a DNA repair and cell-cycle gene expression signature able to discriminate pHGGs (n = 6) from low-grade gliomas (n = 10). This signature was compared to related signatures already established. We used the pHGG signature to explore already transcriptomic datasets of DIPGs and sus-tentorial pHGGs. Finally, we examined the expression of key proteins of the pHGG signature in 21 pHGG diagnostic samples and nine paired relapses. Functional inhibition of one DNA repair factor was carried out in four patients who derived H3.3
RESULTS
RESULTS
We identified a 28-gene expression signature of DNA repair and cell cycle that clustered pHGGs cohorts, in particular sus-tentorial locations, in two groups. Differential protein expression levels of PARP1 and XRCC1 were associated to
CONCLUSION
CONCLUSIONS
We provide evidence that PARP1 overexpression, associated to XRCC1 expression,
Identifiants
pubmed: 34067180
pii: cancers13092252
doi: 10.3390/cancers13092252
pmc: PMC8125831
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Enfants et Santé
ID : 2014
Références
Cancer Res. 2019 Mar 15;79(6):1226-1238
pubmed: 30674534
Neurooncol Adv. 2019 Dec 02;1(1):vdz033
pubmed: 32642664
Cancer Lett. 2020 Jan 28;469:124-133
pubmed: 31669203
Leukemia. 2003 Mar;17(3):532-40
pubmed: 12646941
J Clin Oncol. 2018 Apr 1;36(10):951-958
pubmed: 29412784
Cancer Res. 2010 Nov 15;70(22):9243-52
pubmed: 20935218
DNA Repair (Amst). 2007 Aug 1;6(8):1079-99
pubmed: 17485253
Cancers (Basel). 2019 Nov 26;11(12):
pubmed: 31779235
Acta Neuropathol. 2015 Dec;130(6):815-27
pubmed: 26399631
Elife. 2021 Feb 01;10:
pubmed: 33522486
Cancer Res. 2018 Dec 15;78(24):6818-6827
pubmed: 30297533
BMC Med Genomics. 2019 Sep 18;12(1):132
pubmed: 31533822
Mol Cancer Res. 2020 Nov;18(11):1711-1723
pubmed: 32801164
Bioinformatics. 2012 Mar 15;28(6):882-3
pubmed: 22257669
Clin Cancer Res. 2019 Sep 15;25(18):5572-5583
pubmed: 31227500
Mutat Res. 2019 Apr - Jun;780:37-47
pubmed: 31395347
Cancers (Basel). 2020 Sep 30;12(10):
pubmed: 33007840
Curr Cancer Drug Targets. 2015;15(7):624-40
pubmed: 26118907
Proc Natl Acad Sci U S A. 2018 Sep 18;115(38):9598-9603
pubmed: 30181289
Mol Cancer Ther. 2015 Nov;14(11):2560-8
pubmed: 26351319
Pharmacol Ther. 2018 Sep;189:45-62
pubmed: 29669262
Neuropathol Appl Neurobiol. 2020 Feb;46(1):73-85
pubmed: 31859390
Cancer Cell. 2018 May 14;33(5):829-842.e5
pubmed: 29763623
Cancer Cell. 2017 Oct 9;32(4):520-537.e5
pubmed: 28966033
Sci Rep. 2019 Jul 11;9(1):10075
pubmed: 31296950
PLoS One. 2013 Dec 19;8(12):e82872
pubmed: 24367566
Mol Cancer Res. 2021 Feb;19(2):223-239
pubmed: 33106374
J Neurooncol. 2019 Oct;145(1):177-184
pubmed: 31522324
Cancer Metastasis Rev. 2020 Mar;39(1):245-260
pubmed: 31989507
Nature. 2020 Apr;580(7804):517-523
pubmed: 32322066
Cell Rep. 2014 Jun 26;7(6):2006-18
pubmed: 24931610
Curr Opin Oncol. 2019 Nov;31(6):522-530
pubmed: 31464759
Clin Cancer Res. 2019 Nov 15;25(22):6788-6800
pubmed: 31481512
Neuro Oncol. 2019 Jun 10;21(6):786-799
pubmed: 30852603
Oncotarget. 2011 Dec;2(12):984-96
pubmed: 22184287
Int J Mol Sci. 2020 Dec 17;21(24):
pubmed: 33348922
Nat Struct Mol Biol. 2020 Dec;27(12):1165-1177
pubmed: 33046905
Nat Struct Mol Biol. 2014 Apr;21(4):366-74
pubmed: 24658350
Neuro Oncol. 2011 Mar;13(3):317-23
pubmed: 21339192
Mol Cancer Res. 2020 Jul;18(7):968-980
pubmed: 32229503
Cell Biosci. 2020 Jan 31;10:9
pubmed: 32021684
Eur J Cancer. 2015 May;51(8):977-83
pubmed: 25883011